Equillium, Inc. (EQ)
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Equillium, Inc.
NASDAQ:EQHealthcare · Biotechnology
-3.52%$1.37
AH$1.37+0.00%vs close
Mkt Cap$107.36M
Float62.58M
O/S78.37M
Vol
$ Vol
RVOL
Inst Own53.1%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$22.4M
Total Assets$31.89M
Free Cash Flow-$22.79M
Debt & Equity
Debt 2%
Equity 98%
Total Debt$719K
Total Equity$28.6M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in EQ's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$31.89M
Liabilities$3.29M
Accounts Receivable$108K
Accounts Payable$755K
Inventory$0
PP&E (Net)$658K
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Revenue | $0 | $41.09M | $36.08M | $15.76M | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | 13.9% | 129.0% | - | - | - | - | - | - |
| Cost of Revenue | $116K | $0 | $0 | $0 | $0 | $45K | $23K | $6K | $122 |
| Gross Profit | -$116K | $41.09M | $36.08M | $15.76M | $0 | -$45K | -$23K | -$6K | -$122 |
| Gross Margin | - | 100.0% | 100.0% | 100.0% | - | - | - | - | - |
| Research and Development | $12.84M | $37.43M | $37.04M | $37.55M | $26.38M | $19.38M | $17.64M | $4.94M | $1.33M |
| Selling, General, and Administrative | $10.79M | $11.94M | $13.57M | $17.24M | $11.41M | $10.12M | $9.09M | $3.67M | $378K |
| Other | $0 | $0 | $0 | $23.05M | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $23.63M | $49.36M | $50.61M | $77.83M | $37.79M | $29.5M | $26.73M | $8.62M | $1.71M |
| Operating Income (EBIT) | -$23.63M | -$8.27M | -$14.52M | -$62.08M | -$37.79M | -$29.55M | -$26.73M | -$8.62M | -$1.71M |
| Operating Margin | - | -20.1% | -40.2% | -393.9% | - | - | - | - | - |
| Interest Expense | $0 | $0 | $491K | $1.05M | $1.07M | $1.1M | $279K | $2.56M | $379K |
| Interest Income | $833K | $1.38M | $2.33M | $420K | $57K | $476K | $1.39M | $340K | $0 |
| Other Income (Expense) | $1.24M | $563K | $1.77M | -$352K | -$1.27M | -$265K | $1.13M | -$4.63M | -$550K |
| Income Before Tax (EBT) | -$22.4M | -$7.71M | -$12.76M | -$62.43M | -$39.05M | -$29.81M | -$25.6M | -$13.25M | -$2.26M |
| Income Tax Expense | $0 | $361K | $580K | $0 | $0 | $0 | $0 | $141K | -$2 |
| Net Income | -$22.4M | -$8.07M | -$13.34M | -$62.43M | -$38.98M | -$29.81M | -$25.58M | -$13.25M | -$2.26M |
| Net Income Margin | - | -19.6% | -37.0% | -396.1% | - | - | - | - | - |
| Supplementary Data | |||||||||
| EPS | -0.39 | -0.23 | -0.38 | -3.19 | -1.35 | -1.46 | -1.47 | -1.09 | -0.13 |
| Diluted EPS | -0.39 | -0.23 | -0.38 | -3.19 | -1.35 | -1.46 | -1.47 | -1.09 | -0.19 |
| Weighted Average OS | 91.88M | 35.36M | 34.73M | 33.73M | 28.81M | 20.36M | 17.38M | 12.19M | 11.68M |
| EBITDA | -$22.28M | -$7.57M | -$12.14M | -$61.26M | -$37.91M | -$28.67M | -$25.3M | -$10.69M | -$1.88M |
| EBITDA Margin | - | -18.4% | -33.6% | -388.7% | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Assets | |||||||||
| Current Assets | |||||||||
| Cash and Cash Equivalents | $30.28M | $18.09M | $23.22M | $59.11M | $50.37M | $23.98M | $13.22M | $28.51M | $7.1M |
| Short-Term Investments | $0 | $4.49M | $17.65M | $11.92M | $30.34M | $58.18M | $39.92M | $37.4M | $0 |
| Cash and Short-Term Investments | $30.28M | $22.57M | $40.87M | $71.02M | $80.71M | $82.16M | $53.14M | $65.91M | $7.1M |
| Accounts Receivable | $108K | $1.14M | $6.29M | $4.11M | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | -$547K | $429K | $235K | $8K | $0 | $0 | $0 | $0 | $0 |
| Total Current Assets | $30.28M | $24.98M | $49.35M | $76.73M | $83.37M | $85.17M | $55.54M | $67.16M | $7.15M |
| Long-Term Assets | |||||||||
| Property, Plant & Equipment Net | $658K | $626K | $1.11M | $1.58M | $1.88M | $239K | $93K | $64K | $2K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | $70K | $104K | $153K | $15K | -$93K | $0 | $0 |
| Total Long-Term Assets | $658K | $626K | $1.18M | $1.69M | $2.04M | $254K | $108K | $64K | $2K |
| Other Assets | $952K | $0 | $0 | $0 | $0 | $0 | -$108K | -$64K | $0 |
| Total Assets | $31.89M | $25.6M | $50.53M | $78.42M | $85.41M | $85.43M | $55.54M | $67.16M | $7.15M |
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts Payable | $755K | $2.68M | $4.71M | $3.98M | $1.23M | $2.77M | $1.87M | $1.12M | $244K |
| Short-Term Debt | $363K | $197K | $0 | $5.71M | $1.43M | $1.67M | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $365K | $0 | $0 | $0 | $0 | $0 | $0 | $185K |
| Current Unearned Revenue | $0 | $0 | $15.73M | $14.7M | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $1.82M | $2.68M | $3.64M | $0 | $3.38M | $0 | $795K | $349K | $0 |
| Total Current Liabilities | $2.93M | $6.36M | $27.57M | $32.04M | $8.91M | $7.25M | $3.88M | $2.03M | $569K |
| Long-Term Liabilities | |||||||||
| Long-Term Debt | $356K | $0 | $0 | $3.24M | $8.75M | $8.28M | $9.68M | $0 | $8.06M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $10.38M | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $54K | $127K | $0 | $776K |
| Total Long-Term Liabilities | $356K | $187K | $384K | $14.44M | $9.98M | $8.33M | $9.81M | $200K | $8.83M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3.29M | $6.54M | $27.96M | $46.48M | $18.9M | $15.57M | $13.69M | $2.23M | $9.4M |
| Stockholders' Equity | |||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $5K | $3K | $3K | $3K | $2K | $2K | $1K | $789 | $124 |
| Retained Earnings | -$216.21M | -$193.81M | -$185.74M | -$172.41M | -$109.98M | -$70.92M | -$41.11M | -$15.51M | -$2.26M |
| Comprehensive Income & Other | $363K | $781K | $140K | $76K | -$138K | -$297K | $21K | $5K | $0 |
| Other Stockholders' Equity | $244.8M | $212.87M | $208.31M | $204.34M | $176.48M | $140.78M | $82.96M | $80.45M | $10K |
| Total Equity | $28.6M | $19.06M | $22.57M | $31.94M | $66.5M | $69.85M | $41.85M | $64.94M | -$2.25M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $31.89M | $25.6M | $50.53M | $78.42M | $85.41M | $85.43M | $55.54M | $67.16M | $7.15M |
| Supplementary Data | |||||||||
| Total Debt | $719K | $384K | $824K | $10.19M | $11.79M | $9.94M | $9.68M | $200K | $8.06M |
| Net Debt | -$29.56M | -$17.7M | -$22.39M | -$48.92M | -$38.58M | -$14.04M | -$3.54M | -$28.31M | $955K |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Operating Activities | |||||||||
| Net Income | -$22.4M | -$8.07M | -$13.34M | -$62.43M | -$39.05M | -$29.81M | -$25.6M | -$13.25M | -$2.26M |
| Depreciation & Amortization | $116K | $137K | $126K | $118K | $72K | $45K | $23K | $6K | $122 |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $554K | -$269K | $0 | $0 | $0 |
| Stock-Based Compensation | $2.32M | $3.75M | $4M | $4.84M | $4.41M | $3.82M | $2.25M | $442K | $0 |
| Changes in Working Capital: | |||||||||
| Accounts Receivable | $0 | $3.73M | -$897K | -$2.84M | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$1.94M | -$2M | $723K | $2.51M | -$1.58M | $894K | $775K | $843K | $0 |
| Other Working Capital | -$380K | -$898K | -$2.37M | $349K | $3.28M | $361K | -$62K | -$542K | $435K |
| Total Working Capital Change | -$2.32M | $842K | -$2.55M | $19K | $1.7M | $1.25M | $713K | $301K | $435K |
| Other Non-Cash Items | -$469K | -$15.69M | -$10.03M | $48.72M | $237K | $341K | -$337K | $4.98M | $1.17M |
| Net Cash from Operating | -$22.75M | -$19.03M | -$21.78M | -$8.73M | -$32.08M | -$24.62M | -$22.95M | -$7.53M | -$662K |
| Investing Activities | |||||||||
| Capital Expenditures | -$48K | -$85K | -$50K | -$279K | -$57K | -$202K | -$74K | -$35K | -$2K |
| Acquisitions | $12K | $0 | $0 | $700K | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | -$17.6M | -$54.71M | -$14.96M | -$32.99M | -$55.51M | -$54.62M | -$37.4M | $0 |
| Sales of Investments | $4.5M | $31.5M | $50M | $33.23M | $60.45M | $37.12M | $52.53M | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | $4.46M | $13.81M | -$4.76M | $18.68M | $27.41M | -$18.59M | -$2.17M | -$37.43M | -$2K |
| Financing Activities | |||||||||
| Debt Repaid | - | - | $9.13M | $1.43M | - | - | -$9.88M | -$1.6M | -$7.77M |
| Common Stock Issuance | $30.43M | $164K | $0 | $214K | $29.91M | $53.78M | $0 | $64.47M | $100 |
| Common Stock Repurchases | $0 | $0 | -$260K | $0 | $0 | $0 | -$156K | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $0 | $165K | $0 | $1.15M | $163K | $111K | $292K | $0 |
| Net Cash from Financing | $30.43M | $164K | -$9.23M | -$1.22M | $31.06M | $53.95M | $9.84M | $66.37M | $7.77M |
| Forex Effect | $47K | -$83K | -$118K | $5K | -$2K | $34K | -$10K | $0 | $0 |
| Net Change in Cash | $12.19M | -$5.13M | -$35.89M | $8.74M | $26.38M | $10.76M | -$15.29M | $21.4M | $7.1M |
| Supplementary Data | |||||||||
| Operating Cash Flow | -$22.75M | -$19.03M | -$21.78M | -$8.73M | -$32.08M | -$24.62M | -$22.95M | -$7.53M | -$662K |
| Capital Expenditure | -$48K | -$85K | -$50K | -$279K | -$57K | -$202K | -$74K | -$35K | -$2K |
| Free Cash Flow | -$22.79M | -$19.11M | -$21.83M | -$9.01M | -$32.14M | -$24.83M | -$23.02M | -$7.56M | -$664K |
| Cash at Beginning | $18.09M | $23.22M | $59.11M | $50.37M | $23.98M | $13.22M | $28.51M | $7.1M | $0 |
| Cash at End | $30.28M | $18.09M | $23.22M | $59.11M | $50.37M | $23.98M | $13.22M | $28.51M | $7.1M |